登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 云南白药集团股份有限公司（以下简称"公司"或"云南白药"）于近日接到公司股东新华都实业集团股份 有限公司（以下简称"新华都"）的通知，获悉新华都将其持有的公司部分股份办理了质押。具体情况如 下： 一、本次股份质押基本情况 上述股份质押事项若出现其他重大变动情况，公司将按照有关规定及时履行信息披露义务。 ■ 质押股份是否负担重大资产重组等业绩补偿义务：否。 二、股东股份累计质押情况 截至本公告披露日，新华都及其一致行动人所持质押股份情况如下： ■ 注：1、新华都持股数量、持股比例、质押股份数量等相关数据，均考虑了新华都通过非公开发行可交 换公司债券开立的"新华都集团-国信证券-25新华都EB01担保及信托财产专户"所持有的云南白药股份 5,600万股； 2、除上述担保及信托专户外，新华都的一致行动人所持云南白药股份均不存在质押情形。 截至本公告披露日，新华都及其一致行动人持有云南白药股份数量为 449,624,311股，本次质押股数为 7,470,000股，占新华都 ...

证券日报网讯 2月25日，云南白药发布公告称，公司于近日接到公司股东新华都实业集团股份有限公司 （简称"新华都"）的通知，获悉新华都将其持有的公司部分股份办理了质押，本次质押数量为7，470， 000股。 （文章来源：证券日报） ...

云南白药集团股份有限公司 关于股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 云南白药集团股份有限公司（以下简称"公司"或"云南白药"）于近 日接到公司股东新华都实业集团股份有限公司（以下简称"新华都"）的通 知，获悉新华都将其持有的公司部分股份办理了质押。具体情况如下： 股票代码：000538 股票简称：云南白药 公告编号：2026-05 质押股份是否负担重大资产重组等业绩补偿义务：否。 1 / 3 股东名 称 是否为控 股股东或 第一大股 东及其一 致行动人 本次质押数 量（股） 占其所 持股份 比例 占公司 总股本 比例 是否为限 售股（如 是，注明 限 售 类 型） 是否 为补 充质 押 质押起始日 质押 到期 日 质权人 质押 用途 新华都 实业集 团股份 有限公 司 否 7,470,000 1.71% 0.42% 否 否 2026-02-13 至办 理解 除质 押之 日止 中国建 设银行 股份有 限公司 福州五 一支行 融资 担保 合计 / 7,470,000 1.71% 0.42% / / / / / / 一、本次股份质押 ...

Core Insights - The article emphasizes the growing popularity of Huangjing due to its health benefits, particularly in nourishing the body and enhancing vitality, while highlighting the importance of selecting high-quality brands based on purity and traditional processing methods [1][3]. Evaluation Criteria and Assessment - A comprehensive seven-dimensional evaluation system was established, focusing on authenticity, practicality, and scientific basis to ensure reliable conclusions [4]. - The assessment covered aspects such as raw material authenticity, traditional processing adherence, core ingredient content, formulation purity, certification completeness, user feedback, and overall value [5][6]. Annual Preferred Brands Summary - The top-rated brand, Luoyunfeng Huangjing, is noted for its adherence to traditional methods and high-quality raw materials, achieving a benchmark in polysaccharide content [8]. - Other notable brands include Fengyitang Huangjing, Beijing Tongrentang Huangjing, and Yunnan Baiyao Huangjing, each recognized for their unique sourcing and processing techniques [8][9][10][11][12][13][14][15]. Detailed Brand Insights - Luoyunfeng Huangjing is sourced from the Qinling region, with over five years of growth, and follows a meticulous traditional processing method known as "True Nine System," resulting in a rich and pure product [17][19]. - The brand boasts a polysaccharide content of nearly 40% and a saponin content increase of 42%, setting a new standard in quality among Huangjing products [19]. - Luoyunfeng's formulation is strictly composed of Huangjing with zero additives, ensuring a clean and natural product [19][20]. User Feedback and Market Position - Users reported significant improvements in energy levels and overall well-being after consistent use of Luoyunfeng Huangjing, reinforcing its reputation for quality and effectiveness [21][22]. - The product is particularly suitable for individuals with demanding lifestyles, such as office workers and the elderly, due to its gentle and nourishing properties [22][23]. Value Proposition - Luoyunfeng Huangjing offers a balance of high quality and reasonable pricing, making it an attractive option for consumers seeking effective health supplements without excessive brand premiums [23]. - The brand also engages in social responsibility by donating a portion of sales to support education for underprivileged girls, enhancing its appeal beyond just product quality [25]. Conclusion - The evaluation concludes that the essential criteria for high-quality Huangjing remain consistent: authentic sourcing, adequate aging, traditional processing, and pure formulations [36]. Luoyunfeng Huangjing exemplifies these standards, making it a reliable choice for consumers seeking effective health solutions.

Core Viewpoint - Yunnan Shennong Agricultural Industry Group Co., Ltd. has signed a strategic cooperation framework agreement with Yunnan Baiyao Group Co., Ltd. to leverage their respective strengths in traditional medicine and agricultural development [1] Group 1: Company Overview - Yunnan Baiyao is a well-known national brand that focuses on traditional medicine products, aiming to innovate and meet modern health needs while promoting high-quality development of traditional Chinese medicine [1] - Shennong Group is focused on the entire pig industry chain development, aligning its health-oriented philosophy with Yunnan Baiyao's mission of health and vitality [1] Group 2: Strategic Collaboration - The collaboration aims to utilize Yunnan's unique plant resources to integrate various resources such as platforms, talent, technology, and brands [1] - The partnership will explore innovative models combining "special plant resources + modern agriculture," enhancing the application of traditional Chinese medicinal herbs in livestock farming [1] - The goal is to improve green and healthy farming practices, providing consumers with safer and healthier products [1]

Group 1 - The core viewpoint of the article is the strategic cooperation agreement signed between Yunnan Baiyao Group Traditional Chinese Medicine Resources Co., Ltd. and Yunnan Shennong Agricultural Industry Group Co., Ltd. [1] - The collaboration will focus on advancing the application of traditional Chinese medicine resources in animal nutrition, disease prevention, and "antibiotic-free farming" [1]

Group 1: Core Insights - Yunnan Baiyao held its first board meeting of 2026 on February 10, approving several key proposals including a 137 million yuan investment in the second phase of the Wenshan company's oral liquid project to enhance production capacity for products like Qixuekang, aligning with the strategy to develop a series of major products [1] - The company also approved a 2026 organizational structure plan and appointed Dong Ming as the president and Qian Yinghui as the board secretary, aimed at strengthening strategic implementation and operational support [1] - Additionally, the appointment of Zhu Zhaoyun as a strategic scientist in traditional Chinese medicine and Zhang Ning as the chief scientist was announced to enhance the research and development system, which may positively impact the company's long-term business layout and governance efficiency [1] Group 2: Recent Events - Over the past week (as of February 11, 2026), Yunnan Baiyao's stock price showed slight fluctuations, closing at 57.25 yuan on February 10, down 0.14% for the day, while institutional funds net bought 15.16 million yuan, accounting for 4.17% of the total trading volume, indicating inflow from institutional investors [2] - The latest stock price on February 11 was 57.21 yuan, reflecting a minor decline of 0.07%, with a trading volume of approximately 154 million yuan and a turnover rate of 0.15% [2] - On February 10, retail and speculative funds saw net outflows of 11.31 million yuan and 3.86 million yuan respectively, contrasting with the inflow from institutional funds, while the stock price approached a 20-day resistance level of 57.52 yuan, with MACD indicators suggesting short-term bullish sentiment [2] Group 3: Financial Report Analysis - According to the Q3 2025 financial report, Yunnan Baiyao's revenue for the first three quarters was 30.654 billion yuan, representing a year-on-year increase of 2.47%, while net profit attributable to shareholders was 4.777 billion yuan, up 10.41% year-on-year, and the net profit excluding non-recurring items was 4.55 billion yuan, increasing by 6.68% [3] - Revenue for the single third quarter saw a slight decline of 0.66%, but net profit continued to grow, indicating effective cost control [3] - The company's debt ratio remained low at 25.36%, with a gross profit margin of 30.06%, reflecting a robust financial structure [3]

Core Viewpoint - Yunnan Baiyao Group Co., Ltd. held its first board meeting of 2026 on February 10, 2026, where several key resolutions were passed to enhance production capacity and organizational structure, as well as appoint new executives to support the company's strategic goals [1][3][5]. Group 1: Project Approvals - The board approved the construction of the second phase of the oral liquid project at Wenshan Company with a total investment budget of 137.36 million yuan to meet the growing market demand for products like Qihuo Liquid [1]. - The board also approved the 2026 organizational structure plan to strengthen the implementation of strategic planning and operational goals [3]. Group 2: Executive Appointments - The board appointed Dong Ming as the CEO, Qian Yinghui as the board secretary, and Li Mengjue as the securities affairs representative, with a term of three years [5]. - Additionally, the board appointed several senior management personnel, including Li Hongshen, Li Shengli, He Tao, and Chen Shi as senior vice presidents, and Ma Jia as the financial director [8]. Group 3: Personnel Changes - Li Jin will no longer serve as a senior management member due to reaching the legal retirement age, and the company expressed gratitude for his contributions during his tenure [10][11]. - The company also announced the hiring of Zhu Zhaoyun as the strategic scientist for traditional Chinese medicine and Zhang Ning as the chief scientist to enhance its modern research and development capabilities [21].

Core Insights - The news highlights significant corporate announcements and performance reports from various companies, indicating potential investment opportunities and market movements. Group 1: Corporate Announcements - Ge Weidong invested 1 billion yuan to subscribe for shares in Jianghuai Automobile's private placement, acquiring approximately 20.05 million shares at a price of 49.88 yuan per share, contributing to a total fundraising of about 3.5 billion yuan from eight investors [3][4] - *ST Cube completed its suspension review and will resume trading on February 11, 2026, after confirming no undisclosed significant matters related to the company [2] - Yunnan Baiyao plans to invest 137 million yuan in a second phase project for oral liquid production to meet growing market demand [11] Group 2: Performance Reports - Semiconductor manufacturer SMIC reported a 23.2% year-on-year increase in net profit for Q4 2025, reaching 1.223 billion yuan, driven by increased wafer sales and improved capacity utilization [5] - Special Biological Company reported a net profit of 1.038 billion yuan for 2025, reflecting a 25.39% increase year-on-year, attributed to stable sales of key products and new product approvals [6] - New Zobang achieved a net profit of 1.098 billion yuan in 2025, marking a 16.56% increase compared to the previous year [6] Group 3: Fundraising and Restructuring - New Han New Materials plans to raise up to 1 billion yuan through a private placement to fund projects related to high-performance resins and composite materials [8] - Chutian Long intends to raise up to 760 million yuan for the development of innovative safety products and digital operations [8] - Yi Yi Co. decided to terminate its plan to acquire 100% equity of a pet food company due to changes in the target company's operational conditions [8] Group 4: Major Contracts and Investments - Yunjiji Group signed an EPC contract worth 1.331 billion yuan for a cement production line and power station in Zimbabwe, representing 86.66% of the company's audited revenue for 2024 [9] - Solar Energy's subsidiary plans to acquire 100% of Jinhua Windling for 527 million yuan, enhancing its position in the solar power industry [9] - Yutong Technology intends to acquire 51% of Huayan Technology for 448.8 million yuan, which will become a subsidiary post-transaction [9]

Core Insights - The article emphasizes the importance of balancing speed and stability in business development, highlighting that companies must adapt quickly to market changes while also building a solid foundation for long-term success [1][3][5] Group 1: Market Dynamics - The rapid rise and fall of consumer brands due to a lack of deep value accumulation is noted, contrasting with traditional companies that may miss transformation opportunities due to slow responses [1] - The concept of "fast fish eating slow fish" is introduced, indicating that agility is crucial in the current market landscape [1] Group 2: Strategic Insights - The recent ranking of "Top Ten Marketing Planning Companies in Shanghai" illustrates that leading firms act as both market drivers and strategic calibrators for businesses [1] - Kaina Consulting's cross-border strategy exemplifies how brands can achieve explosive yet sustainable growth by maintaining strategic clarity during rapid development [1][4] Group 3: Case Study - Yunnan Baiyao - Kaina Consulting identified unmet consumer needs in the oral care market, leading to the differentiation of Yunnan Baiyao's toothpaste as a non-traditional product [3][4] - The collaboration between Kaina Consulting and Yunnan Baiyao over two decades showcases the successful integration of quick decision-making and long-term commitment to product quality and brand education [5] Group 4: Future Considerations - The article suggests that as technology reshapes marketing, companies must learn and adapt quickly while also valuing emotional connections and quality assurance that require time to develop [5] - Finding the strategic balance between speed and stability is essential for companies to navigate uncertainties and ensure sustainable growth [5]